ArticleJournal of nephrology2025
Safety of SGLT2 inhibitors in chronic kidney disease patients during Ramadan fasting: a prospective cohort study.
Article in Journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe safety of sodium-glucose co-transporter 2 inhibitors (SGLT2i) during fasting in patients with chronic kidney disease (CKD) remains underexplored. This study investigates the risk of acute kidney injury (AKI) in patients with CKD who are fasting and taking SGLT2i, and also examines the long-term estimated glomerular filtration rate (eGFR) outcomes over 6 months after fasting.
methodsIn this prospective cohort study conducted at the Kidney and Urology Centre, Alexandria, Egypt, 236 Muslim patients with CKD were enrolled during Ramadan. Patients were stratified into two groups: SGLT2i users (n = 56) and non-users (n = 180). Weekly serum creatinine and eGFR were monitored during Ramadan, with monthly follow-up for 6 months post-fasting. AKI was defined as an increase in serum creatinine ≥ 0.3 mg/dL. Logistic regression was used to identify AKI predictors.
resultsThe incidence of AKI was 17.8% among SGLT2i users and 23.3% among non-users (RR 0.76; 95% CI 0.41-1.42; p = 0.38), indicating no significant difference. No significant changes were observed in eGFR between the two groups at the end of Ramadan or during the 6-month follow-up. AKI incidence significantly increased with CKD severity (p = 0.036), with 37.5% of CKD stage 5 patients experiencing at least one episode. Logistic regression identified older age and lower baseline eGFR as significant predictors of developing AKI; SGLT2i use was not independently associated with the risk of developing an AKI episode.
conclusionSGLT2i use in CKD patients during Ramadan fasting does not increase the risk of AKI. These findings may offer valuable guidance for clinicians managing fasting patients with CKD on SGLT2i therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.